AI Drug Discovery for Pharma and Biotech

Drug discovery

9

papers

On emerging therapies

Overview

X-linked spastic paraplegia type 34 (SPG34) is a rare hereditary neurodegenerative disorder characterized by progressive lower limb spasticity, hyperreflexia, and gait disturbances, typically emerging in late childhood to adulthood [2][6]. This pure form of HSP results from X-linked recessive mutations and lacks systemic involvement beyond pyramidal tract degeneration [2][13]. Disease progression is slow but leads to cumulative disability through spastic weakness and reduced mobility [2][7].

Population

  • Affects <1/1,000,000 individuals [2], primarily males due to X-linked inheritance [2][5]. Symptom onset ranges from childhood to early adulthood [2][13].

Burden

  • Progressive mobility loss impacts daily activities and quality of life [8][13]

  • Higher rates of chronic pain (64.8%), urinary dysfunction, and mental health comorbidities [8]

  • Delayed diagnosis common due to symptom overlap with other HSP subtypes [4][16].

Therapies

  • Symptomatic management with antispasmodics (baclofen, tizanidine) [3][7]

  • Botulinum toxin injections for focal spasticity [3][11]

  • Physiotherapy to maintain mobility and prevent contractures [7][11]
    Experimental approaches include salubrinal and gene therapy in preclinical stages [3][15].

Categories: rare genetic diseases, rare neurological diseases

Research Papers

9 drug discovery papers about X-linked spastic paraplegia type 34. Recent publications:

9 drug discovery papers about X-linked spastic paraplegia type 34. Recent publications:

categories:

Small molecules

gene therapies
2022-07-28 | Store-operated calcium entry is reduced in spastin-linked hereditary spastic paraplegia

Pathogenic variants in SPAST, the gene coding for spastin, are the single most common cause of hereditary spastic paraplegia, a progressive motor neuron disease. Spastin regulates key cellular functions, including microtubule-severing and endoplasmic reticulum-morphogenesis. However, it remains unclear how alterations in these cellular functions due to SPAST pathogenic variants result in motor neuron dysfunction. Since spastin influences both microtubule network and endoplasmic reticulum structure, we hypothesized that spastin is necessary for the regulation of Ca2+ homeostasis via store-operated calcium entry. Here, we show that the lack of spastin enlarges the endoplasmic reticulum and reduces store-operated calcium entry. In addition, elevated levels of different spastin variants induced clustering of STIM1 within the endoplasmic reticulum, altered the transport of STIM1 to the plasma membrane and reduced store-operated calcium entry, which could be rescued by exogenous expression of STIM1. Importantly, store-operated calcium entry was strongly reduced in induced pluripotent stem cell-derived neurons from hereditary spastic paraplegia patients with pathogenic variants in SPAST resulting in spastin haploinsufficiency. These neurons developed axonal swellings in response to lack of spastin. We were able to rescue both store-operated calcium entry and axonal swellings in SPAST patient neurons by restoring spastin levels, using CRISPR/Cas9 to correct the pathogenic variants in SPAST. These findings demonstrate that proper amounts of spastin are a key regulatory component for store-operated calcium entry mediated Ca2+ homeostasis and suggest store-operated calcium entry as a disease relevant mechanism of spastin-linked motor neuron disease.

Open article ↗



2013-05-20 | Human “Monogenic” Disease Gene Discovery: When Models of Inheritance Go Wrong

In the era of NGS and WES, geneticists interested in gene discovery want large pedigrees with multiple affecteds, nice clear phenotypes and modes of inheritance, best-practice exclusions of known potential genes, and cohorts of patients with similar phenotypes of unknown genetic aetiology. As we move on to the increasingly rare genetic diseases, multiple pedigrees are more difficult to find. However, as long as the mutations are detectable by WES, we are looking at a straight-forward disease-gene identification, correct? So thought Varga et al. (Hum Mutat 34: 860-863, 2013), who examined not one but two families with hereditary spastic paraplegias (HSPs). The first, from North Africa, had multiple consanguineous marriages, and 4 of 8 children affected from one such union – obviously an autosomal recessive pedigree. WES followed by an analysis for homozygous and segregating truncating mutations found no low-hanging fruit. To help filter the homozygous missense mutations, the authors performed non-parametric linkage (NPL) analysis detecting four genomic regions with a score of greater than 4. However, none of these peaks were confirmed in a parametric analysis assuming AR inheritance. Using the NPL peaks, the authors found a homozygous missense variant in atlastin (ATL1, p.R415Q), a known autosomal dominant HSP gene, in three of the four patients, but also heterozygosity for the same variant in the fourth patient, three unaffected siblings, and both parents. Detailed neurological investigations revealed subclinical signs in 2 of the 5 heterozygous carriers. Thus, the authors concluded that this mutation shows incomplete penetrance in the heterozygous state. The second large family had what appeared to be clear-cut X-linked inheritance with only males affected. WES failed to find an X-linked gene, but revealed a missense mutation affecting the NPL analyses may still be a useful tool as you don't have to trust the pedigree same amino acid residue in ATL1 (p.R415W). With this as the causative variant, there are probably 4 unaffected female carriers and 2 male carriers. The authors concluded that this mutation shows sex-associated incomplete penetrance. They provided further evidence from the literature and a cohort study, as well as evidence that there is a CpG mutation hotspot for ATL1 at codon 415. There are several salient warnings in this study. “The missing inheritance” of HSPs may be due to misinterpretations of inheritance models. Gene hunters beware: NPL analyses may still be a useful tool as you don't have to trust the pedigree. Additionally, the hand waving that varying penetrance may be due to environmental and/or genetic factors is suspect. The genetics of loci encoding other ATL1-interacting proteins such as SPAST (spastin), another HSP gene, may be critical in such patients. With new proteome interaction datasets and technologies such as WES, iPS cells, and cheaper and more efficient genome editing tools such as Zinc Finger (ZF) nucleases, we may be on the verge of unlocking the biological pathways between “simple” epistatic genetic interactions, and thus personalized genotype-to-phenotype predictions – all of future therapeutic relevance.

Open article ↗



gene therapies
2022-07-28 | Store-operated calcium entry is reduced in spastin-linked hereditary spastic paraplegia

Pathogenic variants in SPAST, the gene coding for spastin, are the single most common cause of hereditary spastic paraplegia, a progressive motor neuron disease. Spastin regulates key cellular functions, including microtubule-severing and endoplasmic reticulum-morphogenesis. However, it remains unclear how alterations in these cellular functions due to SPAST pathogenic variants result in motor neuron dysfunction. Since spastin influences both microtubule network and endoplasmic reticulum structure, we hypothesized that spastin is necessary for the regulation of Ca2+ homeostasis via store-operated calcium entry. Here, we show that the lack of spastin enlarges the endoplasmic reticulum and reduces store-operated calcium entry. In addition, elevated levels of different spastin variants induced clustering of STIM1 within the endoplasmic reticulum, altered the transport of STIM1 to the plasma membrane and reduced store-operated calcium entry, which could be rescued by exogenous expression of STIM1. Importantly, store-operated calcium entry was strongly reduced in induced pluripotent stem cell-derived neurons from hereditary spastic paraplegia patients with pathogenic variants in SPAST resulting in spastin haploinsufficiency. These neurons developed axonal swellings in response to lack of spastin. We were able to rescue both store-operated calcium entry and axonal swellings in SPAST patient neurons by restoring spastin levels, using CRISPR/Cas9 to correct the pathogenic variants in SPAST. These findings demonstrate that proper amounts of spastin are a key regulatory component for store-operated calcium entry mediated Ca2+ homeostasis and suggest store-operated calcium entry as a disease relevant mechanism of spastin-linked motor neuron disease.

Open article ↗



2013-05-20 | Human “Monogenic” Disease Gene Discovery: When Models of Inheritance Go Wrong

In the era of NGS and WES, geneticists interested in gene discovery want large pedigrees with multiple affecteds, nice clear phenotypes and modes of inheritance, best-practice exclusions of known potential genes, and cohorts of patients with similar phenotypes of unknown genetic aetiology. As we move on to the increasingly rare genetic diseases, multiple pedigrees are more difficult to find. However, as long as the mutations are detectable by WES, we are looking at a straight-forward disease-gene identification, correct? So thought Varga et al. (Hum Mutat 34: 860-863, 2013), who examined not one but two families with hereditary spastic paraplegias (HSPs). The first, from North Africa, had multiple consanguineous marriages, and 4 of 8 children affected from one such union – obviously an autosomal recessive pedigree. WES followed by an analysis for homozygous and segregating truncating mutations found no low-hanging fruit. To help filter the homozygous missense mutations, the authors performed non-parametric linkage (NPL) analysis detecting four genomic regions with a score of greater than 4. However, none of these peaks were confirmed in a parametric analysis assuming AR inheritance. Using the NPL peaks, the authors found a homozygous missense variant in atlastin (ATL1, p.R415Q), a known autosomal dominant HSP gene, in three of the four patients, but also heterozygosity for the same variant in the fourth patient, three unaffected siblings, and both parents. Detailed neurological investigations revealed subclinical signs in 2 of the 5 heterozygous carriers. Thus, the authors concluded that this mutation shows incomplete penetrance in the heterozygous state. The second large family had what appeared to be clear-cut X-linked inheritance with only males affected. WES failed to find an X-linked gene, but revealed a missense mutation affecting the NPL analyses may still be a useful tool as you don't have to trust the pedigree same amino acid residue in ATL1 (p.R415W). With this as the causative variant, there are probably 4 unaffected female carriers and 2 male carriers. The authors concluded that this mutation shows sex-associated incomplete penetrance. They provided further evidence from the literature and a cohort study, as well as evidence that there is a CpG mutation hotspot for ATL1 at codon 415. There are several salient warnings in this study. “The missing inheritance” of HSPs may be due to misinterpretations of inheritance models. Gene hunters beware: NPL analyses may still be a useful tool as you don't have to trust the pedigree. Additionally, the hand waving that varying penetrance may be due to environmental and/or genetic factors is suspect. The genetics of loci encoding other ATL1-interacting proteins such as SPAST (spastin), another HSP gene, may be critical in such patients. With new proteome interaction datasets and technologies such as WES, iPS cells, and cheaper and more efficient genome editing tools such as Zinc Finger (ZF) nucleases, we may be on the verge of unlocking the biological pathways between “simple” epistatic genetic interactions, and thus personalized genotype-to-phenotype predictions – all of future therapeutic relevance.

Open article ↗



Access all drug discovery papers and probability of success in trials forecasts:

Access all drug discovery papers and probability of success in trials forecasts:

Drug Discovery Landscape

0 orphan drug designations.

0 orphan drug designations.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.

Explority AI logo

228 Park Ave S,
New York, USA.

At Explority, we build first-of-its-kind AI to bring clarity to the earliest and riskiest stages of pharmaceutical research by forecasting which therapies are most likely to succeed. Explority AI web and mobile applications are properties of the Explority AI Inc., a company registered in the United States (File No. 10320493).
For all questions: support@explority.ai

Copyright © 2026 Explority AI Inc.